Cyclosporine A-induced Decrease in Calbindin-D 28 kDa in Rat Kidney but not in Cerebral Cortex and Cerebellum

Recently, we reported that in rat, cyclosporine A (CsA) markedly decreases the levels of calbindin-D (CABP-D) 28 kDa in kidney. CABP-D 28 kDa is a calcium-binding protein which is highly expressed in calcium-transporting tissues such as kidney or brain. In this study, we investigated whether, in add...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical pharmacology 1998-06, Vol.55 (12), p.2043-2046
Main Authors: Varela, Maria del Carmen, Arce, Agustin, Greiner, Brigitte, Schwald, Marianne, Aicher, Lothar, Wahl, Daniel, Grenet, Olivier, Steiner, Sandra
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
brain
Calbindins
calcium-binding protein calbindin-D 28 kDa
cerebellum
Cerebellum - metabolism
Cerebral Cortex - metabolism
Cyclosporine - pharmacology
cyclosporine A
Immunomodulators
Immunosuppressive Agents - pharmacology
kidney
Kidney - metabolism
Male
Medical sciences
Nerve Tissue Proteins - drug effects
Nerve Tissue Proteins - metabolism
Pharmacology. Drug treatments
rat
Rats
Rats, Wistar
S100 Calcium Binding Protein G - drug effects
S100 Calcium Binding Protein G - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, we reported that in rat, cyclosporine A (CsA) markedly decreases the levels of calbindin-D (CABP-D) 28 kDa in kidney. CABP-D 28 kDa is a calcium-binding protein which is highly expressed in calcium-transporting tissues such as kidney or brain. In this study, we investigated whether, in addition to the kidney, CsA also has an effect on CABP-D 28 kDa in rat brain. Three groups of male Wistar rats received 15 mg/kg/day or 50 mg/kg/day of CsA orally for 12 days, whereas controls received vehicle solution for the same period. CABP-D 28-kDa protein and CsA were quantified in homogenates of kidney, cerebral cortex and cerebellum, and the localization of CABP-D 28 kDa was assessed in the different tissue sections by immunohistochemistry. In kidney, CABP-D 28 kDa was strongly and dose dependently decreased, and was located in tubular epithelial cells. In brain, CABP-D 28 kDa was not changed and was mainly located in pyramidal cells of the cortex and in cerebellum exclusively in Purkinje cells. High CsA concentrations were measured in kidney, more than 17-fold greater than those found in cortex. In cerebellum, CsA was below the limit of detection. These data suggest that at clinically relevant doses, CsA may not affect CABP-D 28-kDa levels in brain.
ISSN:0006-2952
1873-2968
DOI:10.1016/S0006-2952(98)00025-2